Venture Capital

ARCH Venture Partners

Investment Details

Investor Type
Venture Capital

Asset Class Focus
Venture Capital, Private Equity, Hedge Funds, Fixed Income (Debt and Bonds), Real Estate, Commodities, Crypto, ESG and Impact Investing, Infrastructure, Collectibles & Art, Distressed and Special Situations

Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed

Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, Singapore, China, India, Brazil, France, Denmark, Switzerland, South Korea, Netherlands, South Africa, New Zealand, Sweden, Israel, Norway, Finland

Industries Focus

  • Technology
  • Healthcare
  • Energy
  • Agriculture
  • Artificial Intelligence
  • Life Sciences
  • Pharmaceuticals
  • Medical Devices
  • Diagnostics
  • Semiconductors
  • Robotics
  • Information Technology
  • Food Technology
  • Quantum Computing
  • Machine Learning
  • Biotechnology
  • Regenerative Medicine
  • Immunotherapy
  • Environmental Technology
  • Materials Science
  • Space Technology
  • Genomics
  • Computing
  • Nanotechnology
  • Physical Sciences

Investment Size:
500,000 to 50,000,000 USD

Investor Details Founded: 1986

ARCH Venture Partners is a prominent venture capital firm that focuses on creating and investing in innovative life science and technology companies. The firm primarily invests in early-stage companies, co-founding and supporting the growth of businesses that aim to prevent, detect, and cure diseases. ARCH's investment philosophy centers on partnering with exceptional scientists and entrepreneurs to bring transformative technologies to market.

The firm's portfolio spans various sectors, including biotechnology, pharmaceuticals, healthcare, medical devices, diagnostics, genomics, immunotherapy, regenerative medicine, artificial intelligence, machine learning, semiconductors, computing, energy, materials science, agriculture, food technology, environmental technology, robotics, space technology, and quantum computing. ARCH's investments are global, with a focus on regions such as the United States, Canada, Europe, Australia, Asia, and Africa.

ARCH's notable early-stage investments include Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Beam Therapeutics, Karuna Therapeutics, Altos Labs, EQRx, National Resilience, Prime Medicine, Lyell Immunopharma, Array BioPharma, Unity Biotechnology, Hua Medicine, Vir Biotechnology, Insitro, Agios Pharmaceuticals, Sage Therapeutics, GRAIL, Gossamer Bio, Ikaria, Kythera Biopharmaceuticals, Receptos, Aviron, Denali Therapeutics, Rubius Therapeutics, Syros Pharmaceuticals, Sana Biotechnology, Verve Therapeutics, Brii Biosciences, Bluebird Bio, R2 Technology, XenoPort, Caliper Life Sciences, Trubion Pharmaceuticals, Adolor, deCODE Genetics, Editas, 10x Genomics, Semma Therapeutics, Element, and IDUN Pharmaceuticals. The firm's investment strategy emphasizes identifying and supporting companies with the potential to revolutionize their respective industries and improve global health outcomes.

ARCH Venture Partners was founded in 1986 and has since established itself as a leader in the venture capital industry, with a strong track record of successful investments and exits. The firm's team comprises experienced professionals with diverse backgrounds in science, technology, and business, enabling them to effectively evaluate and support a wide range of innovative ventures. ARCH's commitment to fostering innovation and driving progress in various sectors continues to make it a key player in the venture capital landscape.

Requirements
  • Focus on early-stage technology and life sciences companies
  • Preference for investments in companies originating from academic institutions and research laboratories
  • Interest in sectors such as biotechnology, semiconductors, and information technology
  • Willingness to invest in companies at the concept stage, often co-founding and developing startups
  • Commitment to backing disruptive science companies with potential for significant impact in their respective fields
Contact

[Official Website Hidden]

[LinkedIn Profile Hidden]

[HQ Location Hidden]

[Email Hidden]

[Contact Number Hidden]

Portfolio Companies
  • Bluebird Bio Inc
  • ClassMates Online Inc
Mentioned In
Claim this Investor

Are you an official representative of ARCH Venture Partners?

Claim this investor to update information, manage your profile, and get a verified seal.

Claim
© 2025 Investorlist.com
Email Support Powered by Kjøller